Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Aug 15;25(11):1708-14.
doi: 10.1002/mds.23168.

Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo

Matthew Menza  1 , Roseanne DeFronzo Dobkin, Humberto Marin, Michael Gara, Karina Bienfait, Allison Dicke, Cynthia L Comella, Charles Cantor, Lee Hyer
Affiliations
Randomized Controlled Trial

Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo

Matthew Menza et al. Mov Disord. .

Abstract

Parkinson's disease (PD) is a common neurodegenerative disease affecting up to 1 million individuals in the United States. Sleep disturbances, typically in sleep maintenance, are found in up to 88% of these individuals and are associated with a variety of poor outcomes. Despite being common and important, there are few data to guide clinical care. We conducted a 6-week, randomized, controlled trial of eszopiclone and placebo in 30 patients with PD and insomnia. Patients with other primary sleep disorders (PSG defined) were excluded. The primary outcome was total sleep time (TST), and secondary measures included wake after sleep onset (WASO), number of awakenings, and quality of sleep, among others. The groups did not significantly differ on TST, but significant differences, favoring eszopiclone, did emerge in number of awakenings (P = 0.035), quality of sleep (P = 0.018), and in physician-rated CGI improvement (P = 0.035). There was also a trend toward significance in WASO (P = 0.071). There were no significant differences between groups in measures of daytime functioning. The drug was well tolerated, with 33% of patients on eszopiclone and 27% of patients on placebo reporting adverse events. Although modest in size, this is the first controlled study of the treatment of insomnia in patients with PD. Eszopiclone did not increase TST significantly but was superior to placebo in improving quality of sleep and some measures of sleep maintenance, which is the most common sleep difficulty experienced by patients with PD. Definitive trials of the treatment of sleep disorders in this population are warranted.

Trial registration: ClinicalTrials.gov NCT00324896.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram
See this image and copyright information in PMC

References

    1. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Disord. 1990;5:280–285. - PubMed
    1. Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson’s disease: A self-reported, community-based survey. Sleep Med. 2002;3:147–149. - PubMed
    1. Scaravelli T, et al. Health related quality of life and sleep disorders in Parkinson’s disease. Neurol Sciences. 2003 Oct;24(3):209–210. - PubMed
    1. Karlsen KH, Tanberg E, Arsland D, Larsen JP. Health related quality of life in P Parkinson’s disease: A prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000 Nov;69:584–589. - PMC - PubMed
    1. Pal PK, et al. Nocturnal sleep disturbances and daytime dysfunction in patients with Parkinson’s disease and in their caregivers. Parkinsonism Relat Disord. 2004 Mar;10(3):157–168. - PubMed

Publication types

Associated data